AML-432 Overall Survival (OS) by IDH2 Mutant Allele (R140 or R172) in Patients With Late-Stage, Mutant-IDH2 Relapsed/Refractory Acute Myeloid Leukemia (AML) Treated With Enasidenib or Conventional Care Regimens (CCR) in the Randomized, Open-Label, Phase 3 IDHENTIFY Trial.

Courtney D DiNardo,Stéphane de Botton,Alberto Risueño,Andre C Schuh,Bob Löwenberg,Hee-Je Kim,Paresh Vyas,Andrew H Wei,Eytan M Stein,Hartmut Döhner,Amir T Fathi, Patricia Martin-Regueira, Lilia Taningco, Iryna Bluemmert, Xin Yu, Wendy L See, Maroof Hasan

Clinical lymphoma, myeloma & leukemia（2022）

引用 0|浏览2

暂无评分

摘要

Mutational burden and co-mutational profiles differed between patients with mIDH2-R140 and mIDH2-R172 relapsed/refractory AML. In the R172 subgroup, median OS and 1-year survival rate with enasidenib were approximately double those with CCR.

查看译文

关键词

AML,IDH2, relapsed/refractory,Phase III,biomarkers,enasidenib

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要